BioSpace News Archive

InspireMD, Inc. announced that a live case demonstration featuring CGuard™ EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022.

Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.

CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern.

AffaMed Therapeutics, licensee of DEXTENZA ® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA ® in China in Cataract Surgery Patients.

Nanalysis Scientific Corp. is pleased to announce that it has entered into a letter of intent to acquire QUAD Systems AG, a Zurich-based Nuclear Magnetic Resonance company focused on high-field NMR for pharmaceutical and other vertical markets.

Endosane Pharmaceuticals and the University of California Irvine have agreed to investigate the efficacy of two innovative compounds for the treatment of post-traumatic stress disorder through a series of preclinical studies.

OSI Systems, Inc. announced that its Optoelectronics and Manufacturing division has received an order for approximately $5 million to provide electronic components to a leading X-ray imaging original equipment manufacturer.

Organophosphates, like methyl-paraoxon, have grown in prominence as effective pest repellants for crops like cotton and legumes.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced the publication of data in the journal Epilepsia from a preclinical study of PRAX-562.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), today announced that the first patient has been enrolled and dosed in a Phase 1b clinical study to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps.